Pitfalls in Gd‐EOB‐DTPA–Enhanced Liver Magnetic Resonance Imaging With an Emphasis on Nontumorous Lesions
Yedaun Lee, So Yeon Kim, Seung Soo Lee, Seong Ho Park, Kyoung Won Kim, Jae Ho Byun, Moon‐Gyu Lee – 7 September 2018
Closing the Quality Chasm in Cirrhosis
Kai Rou Tey, Prashanthinie Mohan, Xibei Liu, Archita P. Desai – 7 September 2018
High‐Mobility Group Box‐1 and Liver Disease
Harriet Gaskell, Xiaodong Ge, Natalia Nieto – 7 September 2018 – High‐mobility group box‐1 (HMGB1) is a ubiquitous protein. While initially thought to be simply an architectural protein due to its DNA‐binding ability, evidence from the last decade suggests that HMGB1 is a key protein participating in the pathogenesis of acute liver injury and chronic liver disease.
PRO: Redistricting of United Network for Organ Sharing Regions to Improve Geographic Disparities in Liver Transplantation
Fernando H. Calmet, Maria Samuel, Paul Martin – 7 September 2018
Geographic Areas of Liver Distribution in the United States Should Not Be Redesigned According to the 2016 Eight‐District Organ Procurement and Transplantation Network Proposal
Jennifer Batisti, Emily A. Schonfeld, Clara Tow, Robert S. Brown – 7 September 2018
Dipeptidyl Peptidase‐4 Is a Pro‐Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells
Nádia Duarte, Inês Coelho, Denys Holovanchuk, Joana Inês Almeida, Carlos Penha‐Gonçalves, Maria Paula Macedo – 7 September 2018 – Dipeptidyl peptidase‐4 (DPP‐4 or clusters of differentiation [CD]26) is a multifunctional molecule with established roles in metabolism. Pharmacologic inhibition of DPP‐4 is widely used to improve glycemic control through regulation of the incretin effect. Colaterally, CD26/DPP‐4 inhibition appears to be beneficial in many inflammatory conditions, namely in delaying progression of liver pathology.
The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Carrie R. Wong, Joseph K. Lim – 7 September 2018
Liver Disease in Cystic Fibrosis: Illuminating the Black Box
Carla Colombo, Gianfranco Alicandro – 6 September 2018
Whole‐Exome Sequencing Study of Extreme Phenotypes of NAFLD
Sarah E. Kleinstein, Matthew Rein, Manal F. Abdelmalek, Cynthia D. Guy, David B. Goldstein, Anna Mae Diehl, Cynthia A. Moylan – 5 September 2018 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH), and advanced stage fibrosis suffer increased risk for complications such as cirrhosis, hepatic decompensation, and liver cancer.
A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis
Carlos J. Pirola, Diego Flichman, Hernán Dopazo, Tomas Fernández Gianotti, Julio San Martino, Cristian Rohr, Martin Garaycoechea, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian – 5 September 2018 – We report on the presence of a rare nonsense mutation (rs149847328, p.Arg227Ter) in the glucokinase regulator (GCKR) gene in an adult patient with nonalcoholic fatty liver disease (NAFLD), morbid obesity, and type 2 diabetes; this patient developed a progressive histological form of the disease.